(Q35928028)

11 August 2017

1 reference

title

Neuroimaging trials of Parkinson's disease progression (English)

1 reference

11 August 2017

0 references

1 reference

John Seibyl

1

1 reference

11 August 2017

Danna Jennings

series ordinal

2

1 reference

11 August 2017

Rowena Tabamo

series ordinal

3

1 reference

11 August 2017

Ken Marek

series ordinal

4

1 reference

11 August 2017

publication date

1 October 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

251 Suppl 7

1 reference

11 August 2017

page(s)

vII9-13

1 reference

https://scigraph.springernature.com/pub.10.1007/s00415-004-1704-5

11 August 2017

exact match

0 references

cites work

[123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00415-004-1704-5

Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00415-004-1704-5

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

12 December 2020

Measuring the progression of idiopathic Parkinson's disease with [123I] beta-CIT SPECT.

1 reference

12 December 2020

Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease

1 reference

12 December 2020

Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

1 reference

12 December 2020

A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Parkinson Study Group

1 reference

12 December 2020

Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

1 reference

12 December 2020

SPECT and PET imaging of the dopaminergic system in Parkinson's disease

1 reference

12 December 2020

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

1 reference

12 December 2020

Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.

1 reference

12 December 2020

[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression

1 reference

12 December 2020

The rate of progression of Parkinson's disease. A longitudinal [18F]DOPA PET study

1 reference

12 December 2020

1 reference

12 December 2020

Imaging the vesicular monoamine transporter

1 reference

12 December 2020

Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group

1 reference

12 December 2020

Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease

1 reference

12 December 2020

Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Parkinson Study Group

1 reference

12 December 2020

Imaging studies in movement disorders

1 reference

12 December 2020

1 reference

12 December 2020

Positron emission tomography studies in movement disorders.

1 reference

12 December 2020

Monitoring neuroprotection and restorative therapies in Parkinson's disease with PET.

1 reference

12 December 2020

Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease.

1 reference

12 December 2020

Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT.

1 reference

12 December 2020

Coenzyme Q10 in neurodegenerative diseases

1 reference

12 December 2020

10.1007/S00415-004-1704-5

Identifiers

DOI

1 reference

11 August 2017

1 reference